Cerebral small vessel diseases (CSVDs) are prominent contributors to vascular cognitive impairment and dementia and can arise from a range of etiologies. Cerebral amyloid angiopathy (CAA) and hypertension (HTN), both prevalent in the elderly population, lead to cerebral microhemorrhages, macrohemorrhages, and white matter damage. However, their respective underlying mechanisms and molecular events are poorly understood. Here, we show that the transgenic rat model of CAA type 1 (rTg-DI) exhibits perivascular inflammation that is lacking in the spontaneously hypertensive stroke-prone (SHR-SP) rat model of HTN. Alternatively, SHR-SP rats display notable dilation of arteriolar perivascular spaces. Comparative proteomics analysis revealed few shared altered proteins, with key proteins such as ANXA3, H2A, and HTRA1 unique to rTg-DI rats, and Nt5e, Flot-1 and Flot-2 unique to SHR-SP rats. Immunolabeling confirmed that upregulation of ANXA3, HTRA1, and neutrophil extracellular trap proteins were distinctly associated with rTg-DI rats. Pathway analysis predicted activation of TGF-β1 and TNFα in rTg-DI rat brain, while insulin signaling was reduced in the SHR-SP rat brain. Thus, we report divergent protein signatures associated with distinct cerebral vessel pathologies in the SHR-SP and rTg-DI rat models and provide new mechanistic insight into these different forms of CSVD.

Diffuse white matter (WM) disease is highly prevalent in elderly with cerebral small vessel disease (cSVD). In humans, cSVD such as cerebral amyloid angiopathy (CAA) often coexists with Alzheimer’s disease imposing a significant impediment for characterizing their distinct effects on WM. Here we studied the burden of age-related CAA pathology on WM disease in a novel transgenic rat model of CAA type 1 (rTg-DI). A cohort of rTg-DI and wild-type rats was scanned longitudinally using MRI for characterization of morphometry, cerebral microbleeds (CMB) and WM integrity. In rTg-DI rats, a distinct pattern of WM loss was observed at 9 M and 11 M. MRI also revealed manifestation of small CMB in thalamus at 6 M, which preceded WM loss and progressively enlarged until the moribund disease stage. Histology revealed myelin loss in the corpus callosum and thalamic CMB in all rTg-DI rats, the latter of which manifested in close proximity to occluded and calcified microvessels. The quantitation of CAA load in rTg-DI rats revealed that the most extensive microvascular Aβ deposition occurred in the thalamus. For the first time using in vivo MRI, we show that CAA type 1 pathology alone is associated with a distinct pattern of WM loss.

Zusammenfassung: Der Beitrag stellt Ergebnisse eines Katasters von Weiterbildungsanbietern in Deutschland vor. Die Erarbeitung des Katasters erfolgte im Rahmen einer Studie, die sich mit den Qualifikationen, den Beschäftigungsbedingungen und den Kompetenzen des Lehrpersonals in der Weiterbildung beschäftigt. Eine Erfassung von Weiterbildungseinrichtungen stellt dafür eine notwendige Voraussetzung dar, da das Lehrpersonal nur über die beschäftigenden Organisationen erreicht werden kann. Zu Beginn wird die Bedeutung eines aktuellen und vollständigen Katasters von Weiterbildungseinrichtungen in Deutschland vor dem Hintergrund des Forschungsstandes und dessen Systematisierung herausgearbeitet. Bisherige Bemühungen zur Abgrenzung, Erfassung und Kategorisierung der Grundgesamtheit organisierter Weiterbildung werden nachgezeichnet und die sich daraus ergebenden Desiderate abgeleitet. Im Anschluss wird das methodische Vorgehen bei der Erstellung, Verifikation, Hochrechnung und Gewichtung des Katasters beschrieben. Auf der Grundlage dieser Daten werden zunächst Informationen zur Zahl der Weiterbildungsanbieter und der Beschäftigungsverhältnisse für das lehrende Personal berichtet und sodann insbesondere im Blick auf ihre regionale Verteilung differenziert analysiert. Abschließend werden Anschlüsse für die Organisations-, die Professionalisierungs- und die Systemforschung der Weiterbildung aufgezeigt.

Fibrillar amyloid β-protein (Aβ) deposits in the brain, which are primarily composed of Aβ40 or Aβ42 peptides, are key pathological features of Alzheimer’s disease (AD) and related disorders. Although the underlying mechanisms are still not clear, the Aβ fibrils can trigger a number of cellular responses, including activation of astrocytes and microglia. In addition, fibril structures of the Aβ40 and Aβ42 peptides are known to be polymorphic, which poses a challenge for attributing the contribution of different Aβ sequences and structures to brain pathology. Here, we systematically treated primary astrocytes and microglia with single, well-characterized polymorphs of Aβ40 or Aβ42 fibrils, and performed bulk RNA sequencing to assess cell-specific changes in gene expression. A greater number of genes were up-regulated by Aβ42 fibril-treated glial cells (251 and 2133 genes in astrocyte and microglia, respectively) compared with the Aβ40 fibril-treated glial cells (191 and 251 genes in astrocytes and microglia, respectively). Immunolabeling studies in an AD rat model with parenchymal fibrillar Aβ42 plaques confirmed the expression of PAI-1, MMP9, MMP12, CCL2, and C1r in plaque-associated microglia, and iNOS, GBP2, and C3D in plaque-associated astrocytes, validating markers from the RNA sequence data. In order to better understand these Aβ fibril-induced gene changes, we analyzed gene expression patterns using the Ingenuity pathway analysis program. These analyses further highlighted that Aβ42 fibril treatment up-regulated cellular activation pathways and immune response pathways in glial cells, including IL1β and TNFα in astrocytes, and microglial activation and TGFβ1 in microglia. Further analysis revealed that a number of disease-associated microglial (DAM) genes were surprisingly suppressed in Aβ40 fibril treated microglia. Together, the present findings indicate that Aβ42 fibrils generally show similar, but stronger, stimulating activity of glial cells compared with Aβ40 fibril treatment.

Our group has previously reported on the phytochemical composition and biological activities of a phenolic-enriched maple syrup extract (MSX), which showed promising anti-inflammatory effects in several disease models including diabetes and Alzheimer's disease. However, the efficacious doses of MSX and its molecular targets involved in the anti-inflammatory effects are not fully elucidated. Herein, the efficacy of MSX in a peritonitis mouse model was evaluated in a dose-finding study and the underlying mechanisms were explored using data-independent acquisition (DIA) proteomics assay. MSX (at 15, 30 and 60 mg kg⁻¹) alleviated lipopolysaccharide-induced peritonitis by reducing the levels of pro-inflammatory cytokines including interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor alpha (TNF-α) in the serum and major organs of the mice. Furthermore, DIA proteomics analyses identified a panel of proteins that were significantly altered (both up- and down-regulated) in the peritonitis group, which were counteracted by the MSX treatments. MSX treatment also modulated several inflammatory upstream regulators including interferon gamma and TNF. Ingenuity pathway analysis suggested that MSX may modulate several signaling pathways in the processes of initiation of cytokine storm, activation of liver regeneration, and suppression of hepatocyte apoptosis. Together, these proteomic and in vivo findings indicate that MSX could regulate inflammation signaling pathways and modulate inflammatory markers and proteins, providing critical insight to its therapeutic potential.

Cerebral amyloid angiopathy (CAA) is a prevalent cerebral small vessel disease (CSVD) and prominent cause of vascular contributions to cognitive impairments and dementia (VCID). CAA is characterized by progressive accumulation of fibrillar amyloid β in cerebral vessel walls, leading to vascular wall degeneration, thrombotic occlusions, microbleeds, and perivascular inflammation causing cognitive deficits. Underlying mechanisms of CAA progression are poorly understood, and there exist no validated diagnostic biomarkers or therapeutic targets for CAA. Here, we performed proteomic mass spectrometry analysis of whole brain tissue and cerebral microvessel enriched fractions from the rTg-DI rat, a validated and well-characterized preclinical rat model of CAA, to identify potential targets and diagnostic markers related to vasculopathy progression in CAA. There were 92 increased and 104 decreased proteins identified in the rTg-DI whole brain samples, while 29 proteins were identified as increased in the enriched cerebral microvessel fractions. We identified several significant differentially expressed proteins in both sample types with commonly elevated proteins including HTRA1, APOE, APOD, CLU, MDK, and LAP3. This study also confirmed the differential expression of several proteins previously reported in isolated brain regions of rTg-DI rats, including ANXA3, APOD, APOE, CLU, CST3, CTSS, CTSD, CTSZ, GFAP, GSTA3, HTRA1, and ITGB2, with APOE, CLU, HTRA1, and GPC1 all reported in human CAA cases. We thus provide a “high-confidence” list of potential marker candidates from proteomic analysis in the rTg-DI rat model of capillary CAA type-1.